Drug Trial Radar · NCT02724020
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Nov 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Jun 30, 2016
Primary completion
Feb 3, 2020
Study completion Oct 13, 2020
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 31, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128 + MLN1117 compared with everolimus in the treatment of participants with metastatic clear-cell renal cell carcinoma (mccRCC) that have progressed on vascular endothelial growth factor (VEGF)-targeted therapy.
Conditions
- Clear-cell Metastatic Renal Cell Carcinoma
Interventions
EverolimusDrug
Everolimus capsules.
MLN0128Drug
MLN0128 capsules.
MLN1117Drug
MLN1117 capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From first dose of study drug up to disease progression or death, assessed up to 43 months
Locations
36 sites in 8 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California
Florida Cancer Specialists-Broadway
Venice, Florida
Florida Cancer Specialists
West Palm Beach, Florida
Hackensack University Medical Center PARTNER
Hackensack, New Jersey
The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital
Columbus, Ohio
Tennessee Oncology
Nashville, Tennessee
The Center for Cancer and Blood Disorders
Weatherford, Texas
CancerCare Manitoba
Winnipeg, Manitoba, Canada
McMaster University
Hamilton, Ontario, Canada
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Groupe Hospitalier Saint Andre - Hopital Saint Andre
Bordeaux, Aquitaine, France
ICL-Alexis Vautrin, Departement dOncologie Medicale
Vandœuvre-lès-Nancy, Meurthe Et Moselle, France
Groupe Hospitalier Pitie-Salpetriere
Paris, Paris, France
Institut de Cancerologie de l'Ouest Paul Papin
Angers, Pays de la Loire Region, France
Clinique Victor Hugo - Centre Jean Bernard
Le Mans, Sarthe, France
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
Bologna, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, Italy
IOV - Istituto Oncologico Veneto IRCCS
Padova, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Beskidzkie Centrum Onkologii im.Jana Pawla II
Bielsko-Biala, Poland
Instytut MSF, Ulica Pilota Stanislawa Wigury 19
Lodz, Poland
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clinic i Provincial de Barcelona
Barcelona, Spain
MD Anderson Cancer Centre
Madrid, Spain
Hospital Universitario Ramon Y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, Spain
Royal Devon and Exeter Hospital (Wonford)
Exeter, Devon, United Kingdom
Lancashire Teaching Hospitals NHS Foundation Trust
Blackburn, England, United Kingdom
Barts Hospital
London, Greater London, United Kingdom
The Christie
Manchester, Greater Manchester, United Kingdom
Velindre Cancer Centre
Cardiff, South Glamorgan, United Kingdom
Royal Surrey County Hospital
Guildford, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.